Curriculum Vitae

Samir P. Kanani M.D.

Radiation Oncology Associates, PC

Department of Radiation Oncology

**Date** April, 6, 2024

**Contact Information**

Business Address: Radiation Oncology Associates, PC

 Inova Fairfax Hospital

Department of Radiation Oncology

3300 Gallows Road

 Falls Church, VA 22042

Business Phone Number: (703) 776-3731

Fax: (703) 776-2743

Email: samir.kanani@inova.org

Foreign Languages: Gujarati

**Education**

1991-1995 B.A., Psychology, University of Texas (Summa Cum Laude)

1995-1999 M.D., University of Texas Medical Branch

**Post Graduate Education and Training**

1999-2000 PGY-1 Transitional Resident, Lehigh Valley Hospital

2000-2004 Residency, Radiation Oncology, University of Maryland Medical Center

2002-2004 Chief Resident, Radiation Oncology, University of Maryland Medical Center

**Certifications**

2005-Current American Board of Radiology (Radiation Oncology)

**Medical Licensures**

Active Maryland

Active Virginia

Inactive Pennsylvania

Inactive North Carolina

**Employment History**

**Academic Appointments**

2008-Present Clinical Assistant Professor, Neurosurgery, George Washington University

2017-2019 Visiting Assistant Professor, Radiation Oncology, University of Maryland School of Medicine (Maryland Proton Treatment Center)

2023-Present Assistant Professor, Medical Education, University of Virginia School of Medicine (Inova Campus)

**Other Employment**

2004-Present Radiation Oncology Associates, PC

INOVA Fairfax Hospital, Department of Radiation Oncology

INOVA Fair Oaks Hospital, Department of Radiation Oncology

INOVA Alexandria Hospital, Department of Radiation Oncology

INOVA Loudoun Hospital, Department of Radiation Oncology

Potomac Radiation Oncology Center

2012-Present Novocure, Consultant and Speakers Bureau: TTF in GBM

2020-Present Veracyte, Consultant and Speakers Bureau: Decipher in Prostate Cancer

**Professional Society Membership**

2000-Present Member, American College of Radiation Oncology

2000-Present Member, American Society of Clinical Oncology

2000-Present Member, Association of Residents in Radiation Oncology

2000-present Member, American Society for Therapeutic Radiology and Oncology (ASTRO)

2001-Present Member, American Association for Cancer Research

2003-Present Member, American Brachytherapy Society

2006-2012 Member, Society of Neuro-oncology

2015-2020 Member, ASTRO Government Relations Committee

**Honors And Awards**

1991-1993 Texas Ex Dedman’s Scholarship, Tuition merit scholarship, UT Austin

1992-1994 Dean’s List College of Liberal Arts, UT Austin

1993-1995 Psi Chi National Honor Society for Psychology, Chapter Vice President

1996-1997 Academic Dean’s List, UTMB

1998 Anesthesiology Clerkship Honors

2002-2004 Chief Resident Radiation Oncology

2008-2023 Washingtonian Top Doctor

**Clinical Activities**

**Clinical Expertise**

Certified Radiation Oncology

Expertise in: Prostate Cancer, Brain Tumors (Benign and Malignant), Lung Cancer, Liver Metastasis, GI Cancers, Proton Radiotherapy, Stereotactic Body Radiation Therapy, Brachytherapy, Intensity Modulated Radiation Therapy and Spine Radiosurgery

**Scope of Clinical Practice:**

2004-present Inova Health Systems Radiation Oncology

(Hospital Radiation Oncology Department)

~ 500 consults per year

~ 400 patients treated per year

~60 Brachytherapy procedures per year

Director of Stereotactic Radiosurgery and Prostate Brachytherapy

**Development of Clinical Programs:**

2004 Development and implementation of IMRT for head and neck tumors

2006 Development and implementation of SBRT for lung tumors

2008 Development and implementation of multidisciplinary Hepatobiliary tumor program

 and Liver Brachytherapy clinic/program

2013 Development and implementation of CyberKnife radiosurgery program

2013 Development and implementation of spine radiosurgery program

2018 Development and implementation of HDR prostate brachytherapy program

2019 Development and implementation of particle therapy program

2020 Development and implementation of multidisciplinary GU clinic/program

2020 Development and implementation of Theragnostic Program

**Administrative Service**

2004-present Member, GU Tumor Board, Inova Fairfax Hospital

2004-present Member, Brain Tumor Board, Inova Fairfax Hospital

2004-present Member, Radiation Oncology electronic library, Inova Fairfax Hospital

2006-2012 Chair, Radiation Safety Committee

2009-present Chief, Prostate Brachytherapy

2019-present Member, GU Cancer Research Steering Committee

2019-present Member, CNS Cancer Research Steering Committee

2019-present Co-Director, MDC GU cancers

**Teaching Service - Resident Teaching**

2008-present Mentor, Preparing Residents for Board Exams and Clinical Teaching/Supervision

 GW University Neurosurgery and Walter Reed Radiation Oncology Residents

 15 residents, 400 contact hours/year

2016 Mentor, Radiation Oncology MOC Oral course (Board Exam Prep)

Walter Reed Radiation Oncology Program

6 residents, 20 contact hours/year

**Peer-reviewed journal articles**

1. Kennedy AS, Ball D, Cohen SJ, Cohn M, Coldwell DM, Drooz A, Ehrenwald E, **Kanani S**, Rose SC, Nutting CW, Moeslein FM, Savin MA, Schirm S, Putnam SG 3rd, Sharma NK, Wang EA. Multicenter evaluation of the safety and efficacy of Raidoembolization in patients with unresectable colorectal liver metastases selected as candidates for (90)Y resin microspheres. J Gastrointest Oncology. 2015 Apr;6(2):134-42.

# Kennedy AS, Ball DS, Cohen SJ, Cohn M, Coldwell DM, Drooz A, Ehrenwald E, **Kanani S**, Nutting CW, Moeslein FM, Putnam SG 3rd, Rose SC, Savin MA, Schirm S, Sharma NK, Wang EA. Hepatic imaging response to radioembolization with yttrium-90-labeled resin microspheres for tumor progression during systemic chemotherapy in patients with colorectal liver metastases. J Gastrointest Oncol. 2015 Dec;6(6):594-604.

# Kennedy AS, Ball DS, Cohen SJ, Cohn M, Coldwell D, Drooz A, Ehrenwald E, **Kanani S**, Rose SC, Nutting CW, Moeslein FM, Savin MA, Schirm S, Putnam SG 3rd, Sharma NK, Wang EA: Metastatic Colorectal Cancer Liver Metastases Outcomes After Radioembolization (MORE) Study Investigators. Safety and Efficacy of Radioembolization in Elderly (>70 Years) and Younger Patients with Unresectable Liver-Dominant Colorectal Cancer. Clin Colorectal Cancer. 2016 Jun;15(2):141-151.e6.

# Narsinh KH, Van Buskirk M, Kennedy AS, Suhail M, Alsaikhan N, Hoh CK, Thurston K, Minocha J, Ball DS, Cohen SJ, Cohn M, Coldwell DM, Drooz A, Ehrenwald E, **Kanani S**, Nutting CW, Moeslein FM, Savin MA, Schirm S, Putnam SG 3rd, Sharma NK, Wang EA, Rose SC. Hepatopulmonary Shunting: A Prognostic Indicator of Survival in Patients with Metastatic Colorectal Adenocarcinoma Treated with 90Y Radioembolization. Radiology. 2017 Jan;282(1):281-288.

1. Kennedy AS, Ball D, Cohen SJ, Cohn M, Coldwell DM, Drooz A, Ehrenwald E, **Kanani S**, Moeslein FM, Nutting CW, Putnam SG 3rd, Rose SC, Savin MA, Schirm S, Sharma NK, Wang EA. Baseline hemoglobin and liver function predict tolerability and overall survival of patients receiving radioembolization for chemotherapy-refractory metastatic colorectal cancer. J Gastrointest Oncol. 2017 Feb;8(1):70-80.

**Non-peer reviewed journal articles**

1. **Kanani, S**: Glioblastoma: Illustrative Case Series Discussion. Clinical Oncology Alert 2011; 27(8)60-61.

**Abstracts**

1. Kennedy A, Murthy R, Kwok Y, **Kanani S**, Tucker G, Desai K, van Echo D: Preliminary results of outpatient hepatic artery brachytherapy for colorectal hepatic metastases. Oral Presentation at ECCO, October 2001.
2. Kennedy A, Murthy R, K wok Y, Tucker G, **Kanani S**, van Echo D: Heptaic artery brachytherapy for unresectable hepatocellular carcinoma: an outpatient treatment approach. Oral Presentation at ICACT, February 2002.
3. **Kanani S**, Kennedy A, Wood A, Dawson N, Edelman M, van Echo D: Preclinical evaluation of chemoradiaton with a novel anti-tubulin agent N, N-dimethyl benzoylphenylurea (BPU) and docetaxel in gastric cancer cell lines. Poster Presentation at AACR, April 2002.
4. **Kanani S**, Suntharalingam M, Wolf J, Duckham E, Gray W, Ord R, et al: Phase I study of concurrent capecitabine and paclitaxel with radiotherapy in locally advanced head and neck cancer. Oral Presentation at RSNA, December 2002.
5. **Kanani S**, Li A, DiBiase S: Correlation of Bladder Neck Dose from Prostate Brachytherapy and Urinary Symptoms. Oral Presentation American Radium Society, May 2004.
6. Andrew S. Kennedy, David Ball, Steven J. Cohen, Michael Cohn, Douglas M. Coldwell, Alain Drooz, Edward Ehrenwald, **Samir Kanani**, Steven C. Rose, Charles W. Nutting, Fred M. Moelein, Michael Savin, Sabine Schirm, Navesh K. Sharma, Eric Wang: U.S. patients receiving resin (90)Y microspheres for unresectable colorectal liver metastases: A multicenter study of 506 patient. J Clin Oncology (30), 2012 (supppl; abstr 3590). Poster ASCO, 2012.
7. Andrew S. Kennedy, David Ball, Steven J. Cohen, Michael Cohn, Douglas M. Coldwell, Alain Drooz, Edward Ehrenwald, **Samir Kanani**, Steven C. Rose, Charles W. Nutting, Fred M. Moeslein, Michael Savin, Sabine Schirm, Navesh K. Sharma, Eric Wang: Hepatic imaging response to (90)Y microsphere therapy administered for tumor progression during systemic chemotherapy in patients with colorectal liver metastases. Poster GI ASCO, 2013.
8. Aduwo J, **Kanani S**, Kapadia S, Kim D, Chapman C, Chawla A, Choe K, Eblan M, Rao A: Stereotactic Body Radiation Therapy Versus High-Dose Rate Brachytherapy Versus Low-Dose Rate Brachytherapy Boost in Combination with Intensity Modulated Radiation Therapy for Localized Prostate Cancer: a Single- Institution Cohort Study. Oral Presentation ASTRO, October 2023.
9. Nwankwo A, Dang, Choe K, **Kanani S**, Cohen A, Ziu M: Is There an Optimal Time to Administer Postoperative Stereotactic Radiosurgery in Patients with Brain Metastases? A Systematic Review of the Literature and Meta-Analysis. Poster Presentation, Society of Neuro-oncology, November 2023.
10. Fan J, Goughenour A, Cernica G, Wang P, Joo M, **Kanani S**, Nie W, Parniani A: Comparative Evaluation of Proton Therapy with Cyberknife Therapy for the Hypo-Fractionated Treatment of Prostate with Focal Boost. Poster Presentation, digital Medical Physics Journal, September 2024.